OBJECTIVE:To study the effect of ormeloxifene in dysfunctional uterine bleeding in premenopausal age group by measuring menstrual blood loss by PBAC score, effect on blood hemoglobin levels and effect on endometrial thickness. METHODS: 35 cases of DUB of age 40 years and above coming to Gynecological OPD were recruited for study after applying exclusion criteria. 60 mg of Ormeloxifene was given twice a week for 3 months and then once a week for 1 month. Patients were followed-up at 1, 3 and 4 months of therapy and then at 3 months after treatment stopped. Menstrual blood loss was measured objectively by pictorial blood loss assessment chart (PBAC) score. RESULTS: The pretreatment median PBAC score was 587 with a range of 186-893. After 4 months of treatment, mean PBAC scores reduced to 76.94±77.73 with a mean change of 490.05±155.4. Which is statistically highly significant (P0.001). 26 (81.25%) patients were cured of menorrhagia at the end of 4 months of treatment. 2 patients had no response and underwent hysterectomy. Amenorrhoea occurred in 22 patients at the end of 4 months of therapy and persisted in 18 patients at 3 months of follow-up after therapy while 1 patient had PBAC scores in the heavy range but much less than her pretreatment levels. Adverse effects included vaginal discharge (15.62%), vague abdominal pain (12.5%), gastric upset (6.25%), headache (6.25%) and ovarian cyst (3.12%). CONCLUSION: Ormeloxifene is an effective and safe therapeutic option for the medical management of perimenopausal DUB.

OBJECTIVE(S):To examine the hypothesis correlating the association of raised maternal serum C-reactive protein levels with the increased risk of preterm labour and to identify the role of infections and inflammations in preterm labor. METHODS/STUDY DESIGN: The prospective study was conducted in 100 primigravida patients with singleton pregnancies aged between 18-35 years. Their quantitative serum C-reactive protein level was measured at 5-20weeks of gestation according to their enrolment in the antenatal clinic. RESULTS: Majority of patients who had serum CRP levels in higher range delivered at preterm. 70% of patients who delivered at preterm had serum CRP levels >7mg/L. None of the patients who had serum CRP levels <2.5mg/L delivered at preterm. 73.3% of preterm patients presented with leaking per vaginum along with other complications, in these patients mean CRP level was 7.6mg/L. CONCLUSION: Our Endeavour in this research was to examine a marker (Serum CRP) which is not only easily sampled but also is cost effective especially in our Indian set up. Raised serum CRP concentrations in early pregnancy are associated with increased risk of preterm birth.

No abstract